Epidermal growth factor receptor cancer associated with

Jackman DM, Yeap BY, Sequist LV et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006 12 3908-3914. 

VanMeter AJ, Rodriguez AS, Bowman ED et al (2008) Laser capture microdissection and protein microarray analysis of human non-smaU cell lung cancer differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics 7 1902-1924... 

Mechanism of Action Ahuman epidermal growth factor that inhibits tyrosine kinases (TK) associated with transmembrane cell surface receptors found on both normal and cancer cells. One such receptor is epidermal growth factor receptor (EGFR). Therapea-tic Effect TK activity appears to be vitally important to cell proliferation and survival. Pharmacokinetics About 60% is absorbed after PO administration bioavailability is increased by food to almost 100%. Protein binding 93%. Extensively metabolized in liver. Primarily eliminated in feces minimal excretion in urine. Half-life 36 hr. 

Erlotinib is an epidermal growth factor receptor inhibitor that inhibits intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor. It is indicated in the treatment of locally advanced or metastatic non-small-cell lung cancer after failure of at least 1 prior chemotherapy regimen. Erlotinib (Tarceva) is a human HER 1/EGER tyrosine kinase inhibitor with the following chemical formula A-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. It is indicated in treatment of patients with locally advanced or metastatic non-small-cell lung cancer. 

Boileau TW, Liao Z, Kim S, Lemeshow S, Erdman JW Jr, Clinton SK (2003) Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J Natl Cancer Inst 95 1578-1586 Bonaccorsi L, Muratori M, Carloni V, Marchiani S, Formigli L, Forti G, Baldi E (2004) The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells. Steroids 69 549-552... 

Trastuzumab (Herceptin) is a humanized monoclonal antibody against the extracellular domain of the human epidermal growth factor receptor 2 (HER2). Treatment of cancer patients with trastuzumab has been associated with an increased incidence of cardiac toxicity including left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death. Trastuzumab can also cause asymptomatic decline in left ventricular ejection fraction (LVEF) (Herceptin PI 2010). 

Stmg TI, Wang YJ, Chen CY, Hung TL, Guo HR. Increased serum level of epidermal growth factor receptor in Kver cancer patients and its association with exposure to arsenic. Sci Total Environ 2012 424 74-8. 

---